MA22866A1 - Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . - Google Patents
Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .Info
- Publication number
- MA22866A1 MA22866A1 MA23157A MA23157A MA22866A1 MA 22866 A1 MA22866 A1 MA 22866A1 MA 23157 A MA23157 A MA 23157A MA 23157 A MA23157 A MA 23157A MA 22866 A1 MA22866 A1 MA 22866A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- neuro
- compounds
- preparation
- degenerative disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA22866A1 true MA22866A1 (fr) | 1993-12-31 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA23157A MA22866A1 (fr) | 1992-04-03 | 1993-04-02 | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633879B1 (en:Method) |
| JP (2) | JP3120810B2 (en:Method) |
| KR (1) | KR100259567B1 (en:Method) |
| CN (1) | CN1044367C (en:Method) |
| AT (1) | ATE163925T1 (en:Method) |
| AU (2) | AU3897693A (en:Method) |
| CA (1) | CA2133427C (en:Method) |
| CZ (1) | CZ288519B6 (en:Method) |
| DE (1) | DE69317411T2 (en:Method) |
| DK (1) | DK0633879T3 (en:Method) |
| DZ (1) | DZ1677A1 (en:Method) |
| ES (1) | ES2115055T3 (en:Method) |
| FI (1) | FI105025B (en:Method) |
| HU (1) | HU211529A9 (en:Method) |
| IL (1) | IL105276A (en:Method) |
| MA (1) | MA22866A1 (en:Method) |
| MX (1) | MX9301935A (en:Method) |
| MY (1) | MY110149A (en:Method) |
| NO (1) | NO302170B1 (en:Method) |
| NZ (1) | NZ251384A (en:Method) |
| PL (1) | PL180014B1 (en:Method) |
| RU (1) | RU2128650C1 (en:Method) |
| SG (1) | SG47948A1 (en:Method) |
| SK (1) | SK281258B6 (en:Method) |
| TW (1) | TW282455B (en:Method) |
| UA (1) | UA29437C2 (en:Method) |
| WO (1) | WO1993020052A1 (en:Method) |
| ZA (1) | ZA932415B (en:Method) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) * | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
| ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| AR030676A1 (es) * | 1999-07-28 | 2003-09-03 | Ortho Mcneil Pharm Inc | Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| SA109310013B1 (ar) * | 2008-12-24 | 2013-07-28 | Astrazeneca Ab | مركبات إيثان أمين وطرق لتحضيرها |
| JP2015501652A (ja) * | 2011-12-14 | 2015-01-19 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｇａｂｒ−ａ２診断 |
| RU2695372C2 (ru) * | 2013-11-05 | 2019-07-23 | Астразенека Аб | Пролекарства антагониста NMDA |
| EP4168116A4 (en) * | 2020-06-23 | 2024-07-10 | Biohaven Therapeutics Ltd. | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK689388A (da) * | 1987-12-11 | 1989-06-12 | Syntex Lab | Anvendelse af dihydropyridinderivater |
| ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
-
1993
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/en not_active Ceased
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 EP EP93907975A patent/EP0633879B1/en not_active Expired - Lifetime
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 CA CA002133427A patent/CA2133427C/en not_active Expired - Lifetime
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG20218A (en) | Process for preparing of substituted 3 aminoquinuclidines | |
| EP0668750A4 (en) | PEDICULAR SCREW AND INSTRUMENTS FOR REAR SPINE CORRECTION. | |
| MA22626A1 (fr) | Procede de preparation d'acides imidazolyl-alcenoiques . | |
| FR2690855B1 (fr) | Adsorbants pour l'elimination de hcl et procede pour leur production et leur utilisation. | |
| MA26410A1 (fr) | Formulations pharmaceutiques et procede pour leur production. | |
| BG101118A (en) | Therapeutical compounds | |
| FR2740132B1 (fr) | Procede pour la preparation de 1,1,1,3,3-pentafluoropropane | |
| MA22866A1 (fr) | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . | |
| EP0673384A4 (en) | POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES. | |
| FR2705966B1 (fr) | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. | |
| MA23134A1 (fr) | Procede pour la preparation d'aryl-piperidine carbinols . | |
| CA2217513A1 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
| MA23663A1 (fr) | Procede de preparation de formulations pharmaceutiques | |
| MA22278A1 (fr) | Procede pour le traitement de troubles respiratoires | |
| FR2700956B1 (fr) | Composition cosmetique et pharmaceutique et procede pour sa preparation. | |
| FR2733227B1 (fr) | Procede pour la preparation de 1,1-difluoroethane | |
| MA23081A1 (fr) | Procede de preparation de derives d'indolone | |
| FR2677354B1 (fr) | Procede pour la preparation d'esters d'acides racemisables. | |
| MA23953A1 (fr) | Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites | |
| IL99236A0 (en) | Pharmaceutical composition for the topical treatment of psoriasis | |
| FR2703286B1 (fr) | Procede d'usinage des chants de dalles de pierre et appareil le mettant en oeuvre. | |
| FR2673635B1 (fr) | Procede pour la preparation d'une composition aerosol. | |
| FR2736635B1 (fr) | Procede de preparation d'alpha,omega-bromochloroalcanes | |
| FR2696171B1 (fr) | Procede de preparation du divinylbenzene. | |
| FR2676583B1 (fr) | Procede pour la desorption d'iode de fission. |